January 26, 2011
Marcia Boyle, President and Founder, Immune Deficiency Foundation
AOL News
Thirty years ago my infant son was diagnosed with a rare genetic disorder that make even common cold germs potentially life threatening. His disorder — clinically termed a primary immunodeficiency disease — started me on my career as a patient activist.
December 14, 2010
John Horton, President, LegitScript
Huffington Post
Where there’s medicine, there’s money. That statement should come as no surprise to anyone who has ever looked at a medical bill or filled a prescription: Pharmaceuticals alone are a more than $800-billion market ($300 billion of that is in the United States alone).
December 14, 2010
Biologic drugs can treat a variety of illnesses—including cancer and certain types of arthritis—imore effectively than traditional, chemical based products. For this reason, the medical community is excited about the potential of these so called “miracle drugs.” Continue reading…
December 14, 2010
Biologic drugs can treat a variety of illnesses—including cancer and certain types of arthritis—imore effectively than traditional, chemical based products. For this reason, the medical community is excited about the potential of these so called “miracle drugs.” Continue reading…
December 14, 2010
Biologic drugs are often referred to as ”miracle drugs“ for good reason—they can often treat serious illnesses such as cancer, rheumatoid arthritis, and multiple sclerosis far more effectively than the traditional chemical drugs that preceded them. Continue reading…
December 14, 2010
Biologic drugs are often referred to as ”miracle drugs“ for good reason—they can often treat serious illnesses such as cancer, rheumatoid arthritis, and multiple sclerosis far more effectively than the traditional chemical drugs that preceded them. Continue reading…
November 15, 2010
Dr. Edward Treadwell, Department of Internal Medicine at the Brody School of Medicine at East Carolina University in Greenville, N.C.
Buffalo News
Americans elected a new Congress on Nov. 2, but the voting booth wasn’t the only place where critical issues were at stake that day. Away from the spotlight of election news coverage, a committee of the federal Food and Drug Administration held a hearing in a Washington suburb on the future of biologic drugs, perhaps the most promising health care breakthrough of our lifetime.
November 15, 2010
Dr. Edward Treadwell, Department of Internal Medicine at the Brody School of Medicine at East Carolina University in Greenville, N.C.
Buffalo News
Americans elected a new Congress on Nov. 2, but the voting booth wasn’t the only place where critical issues were at stake that day. Away from the spotlight of election news coverage, a committee of the federal Food and Drug Administration held a hearing in a Washington suburb on the future of biologic drugs, perhaps the most promising health care breakthrough of our lifetime.
November 11, 2010
Dr. Edward Treadwell, Department of Internal Medicine at the Brody School of Medicine at East Carolina University in Greenville, N.C.
Tampa Tribune
Away from the spotlight of election news coverage, a committee of the U.S. Food and Drug Administration (FDA) held a hearing in a Washington suburb on the future of biologic drugs, perhaps the most promising health care breakthrough of our lifetime.
November 7, 2010
John Horton, President, LegitScript
Huffington Post
For cancer patients, what is the “acceptable risk” that a drug will pose safety risks or won’t work properly? That’s one of the thorny questions addressed by the FDA last week in a two-day, open-to-the-public meeting about “biosimilar” drugs — second-generation versions of drugs made from living organisms, or “biologics.”
